Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market
Executive Summary
Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price of Roche’s innovator Rituxan. The launch marks Teva's first biosimilar launch in the US.
You may also be interested in...
US Biosimilars Strength Rides On The Wings Of Oncology Launches
Herceptin, Avastin and Rituxan biosimilars have achieved notable market penetration, outpacing other biosimilar launches and contributing to lower drug spending, according to a report from Amgen.
Biosimilar Uptake Gains Momentum In The US
Getting doctors to prescribe lower cost biologics has become less of a challenge as additional products reach the market in the US, according to panelists at the World Biosimilar Congress.
Payer, Provider Strategies To Encourage Biosimilar Uptake Gain Momentum
Getting doctors to prescribe lower cost biologics has become less of a challenge as additional products reach the market in the US, according to panelists at the World Biosimilar Congress.